Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 20c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 20c, Revenues Miss

Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 7, 2020 7:30 AM EDT

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2020, and provided a corporate update.

In the midst of these unprecedented times we are proud of the agile adaptation of our organization to successfully execute a virtual launch of CAPLYTA, a new treatment option for adult patients suffering from schizophrenia, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. Beyond our... More